CSL Share Price 'Most Attractive' in Uncertain Times, Says Fund Manager

2 min read | November 02, 2023 07:28 PM AEDT | By Team Kalkine Media

The CSL Ltd (ASX:CSL) share price is standing out among ASX healthcare stocks during the current market rally. CSL shares closed at $234.98 and have since risen to $237.63, marking a 1.1% gain in line with the broader 1.2% increase in the ASX 200 at the same time. Jun Bei Liu, a fund manager at Tribeca Investment Partners, has expressed her confidence in the CSL share price, highlighting its potential to outperform over the long term. She cited CSL's impressive track record, having built a world-leading blood plasma franchise through strategic acquisitions and a focus on efficiency and robust sales and marketing capabilities over the last 25 years. 

CSL operates in three distinct business segments: blood plasma, influenza vaccines, and injectable iron, all of which offer solid medium-term growth prospects, providing diversified and defensive earnings streams. In the face of economic uncertainties, rising interest rates, and geopolitical threats, investors are increasingly favoring defensive stocks. Liu believes that this shift will work in favor of the CSL share price, which has historically shown its attractiveness during periods of investor uncertainty. With new and competing therapies emerging in all three of its business segments, CSL appears to be in such a period now. 

Liu also emphasized that CSL's strong management team has guided the company to double-digit earnings growth over the medium term, highlighting its continued position as a growth company. The company reported robust FY 2023 results, including a 31% YoY increase in revenue (in constant currency) to US$13.31 billion and a 20% YoY rise in net profit after tax before amortization (NPATA) to US$2.86 billion (in constant currency). These positive results contributed to a 3.7% increase in the CSL share price on the day of the announcement. Despite the challenges and competition across its three business segments, CSL remains well-prepared to navigate and sustain its growth, making it an appealing choice for investors in uncertain times. 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.